Covalon Technologies (Covalon Technologies) Net Change in Cash : $-2.62 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Covalon Technologies Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Covalon Technologies's Net Change in Cash for the three months ended in Mar. 2024 was $-0.76 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.62 Mil.

Covalon Technologies Net Change in Cash Historical Data

The historical data trend for Covalon Technologies's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covalon Technologies Net Change in Cash Chart

Covalon Technologies Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Net Change in Cash

Get a 7-Day Free Trial

3.09

-5.70

-5.67

-7.18

-4.91

Covalon Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															-2.41	-1.19	-0.29	-0.38	-0.76

Covalon Technologies Net Change in Cash Calculation

Covalon Technologies's Net Change in Cash for the fiscal year that ended in Sep. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-2.353	+	-1.073	+	-1.593	+	0.114
	=	-4.91

Covalon Technologies's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.732 + -0.132 + -0.078 + 0.18

= -0.76

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Covalon Technologies Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Covalon Technologies's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Covalon Technologies (Covalon Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Covalon Technologies Ltd (OTCPK:CVALF) » Definitions » Net Change in Cash

Comparable Companies

TSXV:CYTO NEOE:BMND TSX:APS XCNQ:DOSE TSXV:GSD TSXV:TTI XCNQ:TELI TSXV:CZO TSXV:NRX XCNQ:GLAB OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX

Traded in Other Exchanges

COV:Canada

Address

1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7

Website

https://www.covalon.com

Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops advanced wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.

Covalon Technologies (Covalon Technologies) Headlines

From GuruFocus

Closing Chronic Wounds with Collagen Powder: University of Michigan case study demonstrates the efficacy of ColActive Plus Powder in resolving non-healing wounds
By PRNewswire PRNewswire • 11-01-2022

Compassionate Care Solutions Provider Covalon Participating in the Canadian Vascular Access Association and World Congress on Vascular Access Joint Conference on April 26-28, 2023 in Toronto
By PRNewswire PRNewswire • 04-26-2023

Infection Prevention Solutions Provider Covalon to Participate for the First Time in NEO - The Conference for Neonatology in Las Vegas, NV on February 22-24, 2023
By PRNewswire PRNewswire • 02-20-2023

Covalon Attracts Well-Known Medical Industry Sales Executive
By PRNewswire PRNewswire • 06-28-2022

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results
By PRNewswire PRNewswire • 06-25-2022

Leader in Compassionate Care Infection Prevention Solutions, Covalon, to Participate in the Synova NICU Leadership Forum 2023 in Tucson, Arizona from March 19 to 23, 2023
By PRNewswire PRNewswire • 03-20-2023

Covalon Announces Second Quarter Fiscal 2022 Results
By PRNewswire PRNewswire • 06-09-2022

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results
By PRNewswire PRNewswire • 06-15-2022

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results
By PRNewswire PRNewswire • 07-05-2022

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2022 Financial Results
By PRNewswire PRNewswire • 07-15-2022